arrow
M

Masayuki Kanamori

Tohoku University
H指数:35
被引数:4,154

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

LncRNA CCDC152 coordinates a tumor-associated selenoprotein P cycle that sustains selenium-dependent redox homeostasis in glioblastoma

长链非编码RNA <em>CCDC152</em> 协调一种肿瘤相关硒蛋白P循环,以维持胶质母细胞瘤中硒依赖性的氧化还原稳态

2026-10-120
OAAI
Glioma Segmentation on Multicenter 2D-Based Magnetic Resonance Imaging Using Low-Rank Adaptation Tuning of a Foundation Model: An External Test Evaluation

基于低秩适应调优的基础模型在多中心2D磁共振成像上的胶质瘤分割:一项外部测试评估

2026-08-310
PRE
Clinical utility of comprehensive genomic profiling tests using MTB management system at a single center in Japan

日本单中心利用MTB管理系统进行综合基因组分析测试的临床应用价值

2026-07-070
OA
Tectal glioma with pilocytic astrocytoma morphology carrying a histone H3 K27M mutation and malignant transformation: a literature review

室管膜胶质瘤伴毛细胞型星形细胞瘤形态,携带组蛋白H3 K27M突变和恶性转化:文献综述

2026-05-130
PRE
Molecular and clinical features of a Japanese medulloblastoma cohort: Subgroup-specific prognostic stratification using economical/accessible diagnostic methods

日本髓母细胞瘤队列的分子与临床特征:采用经济/便捷的诊断方法进行亚组特异性预后分层

2026-03-110
OAAI
Preoperative assessment of perforating arteries around amygdala glioblastoma using intra-arterial CT angiography with ultra-high-resolution CT and MR tractography: a case report

杏仁体胶质母细胞瘤周围穿通动脉的术前评估:采用超高清CT与MR束状追踪技术的经动脉CT血管造影病例报告

2025-12-110
OAAI
Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas

II期研究:safusidenib erbumine在化疗和放疗初治的异柠檬酸脱氢酶1突变型WHO II级胶质瘤患者中的应用

2025-11-080
OAAI
A multicenter phase II trial of convection-enhanced delivery of ACNU in children with DIPG: Comparison with Japanese historical control and examination of patient selection bias

一项关于ACNU对流增强递送在儿童DIPG中的多中心II期临床试验:与日本历史对照的比较及患者选择偏倚的考察

2025-11-010
PRE
Molecular Mechanisms and Developmental Pathways of CNS Germ Cell Tumors Elucidated through Whole Genome Analysis

CNS生殖细胞肿瘤的分子机制与发育通路,通过全基因组分析进行阐明

2025-11-010
OAAI
RESULTS OF PHASE II STUDY OF NIVOLUMAB FOR PATIENTS WITH MENINGIOMAS REFRACTORY TO SURGERY AND RADIOTHERAPY BASED ON IMMUNE-RELATED RESPONSE CRITERIA WITH MOLECULAR ANALYSES

基于免疫相关反应标准及分子分析的尼鲁单抗治疗对手术和放疗无效的脑膜瘤患者的II期研究结果

2025-11-010
OAAI